SecBot SecBot
144 ·Filed Jun 26, 2026

PSNL

Personalis, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed4mo ago SEC0001950047-26-006542
Form 144, notice of proposed sale of securities
Actionable Insight • Neutral

This is a routine pre-planned sale under a 10b5-1 trading plan by a director/officer. The amount is modest relative to market cap. No material signal for the stock. Monitor for any acceleration in selling or deviation from the plan.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$13.75
T+0 close · Jun 26, 2026 · via day close
Latest settled
+18.98%
T+60 · $16.36
Vs SPY
+14.60%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 29 $13.75entry
  2. T+1 · 5mo ago −2.55%α −3.32% · $13.40
  3. T+5 · 4mo ago +4.29%α +2.90% · $14.34
  4. T+20 · 4mo ago −14.33%α −14.05% · $11.78
  5. T+60 · 8w ago +18.98%α +14.60% · $16.36
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Director and Officer Christopher Hall filed a Form 144 indicating intent to sell 100,000 shares of Personalis common stock, valued at approximately $1.26 million, on June 26, 2026. The sale is part of an existing 10b5-1 trading plan, with prior sales of ~$1.1M in late May, making this a routine pre-planned transaction.

Key Facts

  • Insider Christopher Hall (Director & Officer) intends to sell 100,000 shares of PSNL common stock.
  • Estimated market value of proposed sale: $1,259,000.
  • Sale is scheduled for June 26, 2026, on NASDAQ.
  • Shares are acquired through exercise of stock options.
  • Sale is part of a pre-existing 10b5-1 trading plan; prior sales under the plan occurred on May 28-29, 2026 (total ~100,000 shares for ~$1.1M).
  • Proposed sale represents ~0.09% of PSNL's $1.4B market cap.

Financial Impact

Proposed sale of $1.26M in PSNL common stock, representing ~0.09% of market cap.

dilution

Risk Factors

  • Potential for further insider selling if the 10b5-1 plan is expanded or if additional plans are adopted.

Market Snapshot

Exchange
Nasdaq
Sector
Services-Medical Laboratories
Analyst Consensus
85% bullish (13 analysts)

Investment Themes

Healthcare & Medical Devices

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
144 Filing (Primary)0001950047-26-006542
Document: 0001950047-26-006542-index.html0001950047-26-006542
Document: 0001950047-26-006542.txt0001950047-26-006542

Track record

29 reports on PSNL

Performance horizon

4 of 6 bullish or bearish reports moved the stock their way by T+60. Best: +18.82% at T+60 after the Jul 20, 2026 report. 8 of 9 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $15.16 Now $14.80 −2.34% settles Feb 12
  2. Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $15.71 Now $14.80 −5.79% settles Feb 11
  3. Nov 12, 20264d ago 425 Neutral 4/10 Entry $15.86 Now $14.80 −6.68% settles Feb 10
  4. Nov 6, 202610d ago 425 Neutral 3/10 Entry $15.95 Now $14.80 −7.21% settles Feb 5
  5. Nov 4, 202612d ago 8-K Neutral 5/10 Entry $15.55 Now $14.80 −4.82% settles Feb 3
  6. Nov 3, 202613d ago 425 Neutral 3/10 Entry $15.79 Now $14.80 −6.27% settles Feb 2
  7. Oct 30, 202617d ago 425 Neutral 4/10 Entry $15.76 Now $14.80 −6.09% settles Jan 29
  8. Oct 21, 202626d ago DEFM14A Neutral 5/10 Entry $15.82 Now $14.80 −6.45% settles Jan 20
  9. Oct 20, 202627d ago 425 Neutral 4/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
  10. Oct 20, 202627d ago 425 Neutral 5/10 Entry $15.90 Now $14.80 −6.92% settles Jan 19
Showing 10 of 29

US Market Status

Market Closed · Opens in 8h 47m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 3, 2026